Lilly’s Retevmo® (selpercatinib, 40 mg & 80 mg capsules) is approved by the U.S. Food...
- FDA Approves First Therapy Specific for RET-Driven Lung and Thyroid Cancers
- The Plate Method for Managing Diabetes and Other Inflammatory Diseases
- Positive Topline Results for Patients with Heart Disease
- Great News for High-Risk Breast Cancer Patients
- FDA’s Expanded Indication Treats More People with Heart Failure